<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vericel Corp Ord — News on 6ix</title>
<link>https://6ix.com/company/vericel-corp-ord</link>
<description>Latest news and press releases for Vericel Corp Ord on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vericel-corp-ord" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d15c78dffbe2df11fad1.webp</url>
<title>Vericel Corp Ord</title>
<link>https://6ix.com/company/vericel-corp-ord</link>
</image>
<item>
<title>Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-announces-barda-award-valued-at-up-to-dollar197-million-for-procurement-and-advanced-development-of-nexobrid</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-announces-barda-award-valued-at-up-to-dollar197-million-for-procurement-and-advanced-development-of-nexobrid</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-announces-fda-approval-of-new-state-of-the-art-advanced-therapy-manufacturing-facility-12</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-announces-fda-approval-of-new-state-of-the-art-advanced-therapy-manufacturing-facility-12</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential</description>
</item>
<item>
<title>Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 12:55:00 GMT</pubDate>
<description>Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financi</description>
</item>
<item>
<title>Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-report-fourth-quarter-full-133000800</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-report-fourth-quarter-full-133000800</guid>
<pubDate>Thu, 12 Feb 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations s</description>
</item>
<item>
<title>Vericel Announces Preliminary 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-announces-preliminary-2025-financial-results-and-business-updates-2026-01-13</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-announces-preliminary-2025-financial-results-and-business-updates-2026-01-13</guid>
<pubDate>Tue, 13 Jan 2026 05:00:00 GMT</pubDate>
<description>Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE,</description>
</item>
<item>
<title>Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-present-44th-annual-jp-morgan-healthcare-conference-wednesday-january-14-2026</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-present-44th-annual-jp-morgan-healthcare-conference-wednesday-january-14-2026</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel to Present at the Stephens Annual Investment Conference on Thursday, November 20, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-present-stephens-annual-investment-conference-thursday-november-20-2025-2025</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-present-stephens-annual-investment-conference-thursday-november-20-2025-2025</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-reports-third-quarter-2025-financial-results-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-reports-third-quarter-2025-financial-results-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Record Third Quarter Total Revenue of $67.5 Million MACI Revenue Growth of 25% to $55.7 Million Net Income of $5.1 Million and Adjusted EBITDA Margin of 25%</description>
</item>
<item>
<title>Vericel to Report Third-Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-report-third-quarter-2025-financial-results-november-6-2025-2025-10-23</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel to Present at the Wells Fargo Healthcare Conference on Thursday, September 4, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-present-wells-fargo-healthcare-conference-thursday-september-4-2025-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-present-wells-fargo-healthcare-conference-thursday-september-4-2025-2025-08</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-reports-second-quarter-2025-financial-results-2025-07-31</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-reports-second-quarter-2025-financial-results-2025-07-31</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74%</description>
</item>
<item>
<title>Vericel to Report Second-Quarter 2025 Financial Results on July 31, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-report-second-quarter-2025-financial-results-july-31-2025-2025-07-17</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-report-second-quarter-2025-financial-results-july-31-2025-2025-07-17</guid>
<pubDate>Thu, 17 Jul 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-present-truist-securities-medtech-conference-tuesday-june-17-2025-2025-06-10</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-present-truist-securities-medtech-conference-tuesday-june-17-2025-2025-06-10</guid>
<pubDate>Tue, 10 Jun 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-reports-first-quarter-2025-financial-results-and-raises-full-year</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-reports-first-quarter-2025-financial-results-and-raises-full-year</guid>
<pubDate>Thu, 08 May 2025 04:00:00 GMT</pubDate>
<description>Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date,</description>
</item>
<item>
<title>Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-present-bank-america-securities-2025-healthcare-conference-wednesday-may-14</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-present-bank-america-securities-2025-healthcare-conference-wednesday-may-14</guid>
<pubDate>Wed, 07 May 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-report-first-quarter-2025-financial-results-may-8-2025-2025-04-24</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-report-first-quarter-2025-financial-results-may-8-2025-2025-04-24</guid>
<pubDate>Thu, 24 Apr 2025 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel to Present at Multiple Upcoming Investor Conferences</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-present-multiple-upcoming-investor-conferences-2025-03-04</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-present-multiple-upcoming-investor-conferences-2025-03-04</guid>
<pubDate>Tue, 04 Mar 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
<item>
<title>Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-reports-fourth-quarter-and-full-year-2024-financial-results-2025-02-27</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-reports-fourth-quarter-and-full-year-2024-financial-results-2025-02-27</guid>
<pubDate>Thu, 27 Feb 2025 05:00:00 GMT</pubDate>
<description>Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth</description>
</item>
<item>
<title>Vericel to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 27, 2025</title>
<link>https://6ix.com/company/vericel-corp-ord/news/vericel-report-fourth-quarter-and-full-year-2024-financial-results-february-27-2025</link>
<guid isPermaLink="true">https://6ix.com/company/vericel-corp-ord/news/vericel-report-fourth-quarter-and-full-year-2024-financial-results-february-27-2025</guid>
<pubDate>Thu, 13 Feb 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn</description>
</item>
</channel>
</rss>